Pharmacopeia

CWP-0232

Rifaximin

Gastrointestinal · Level 3

Core pharmacology

Class Group

Poorly absorbed rifamycin-derived antibiotic acting primarily within the gastrointestinal lumen.

Main Action

Reduces intestinal bacterial load and ammonia generation, helping prevent recurrent hepatic encephalopathy.

Mechanism of action

Binds bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis; acts predominantly within the gut.

Indications Uses

Australian Xifaxan 550 mg indication: prevention of recurrent hepatic encephalopathy when other treatments have failed or are contraindicated; often used alongside lactulose.

Route And Dose

Oral 550 mg twice daily is the Australian labelled regimen for prevention of recurrent hepatic encephalopathy. Indications/regimens for other uses vary by jurisdiction.

Absorption

Very low systemic absorption in healthy subjects; systemic exposure is greater in advanced hepatic impairment despite gut-selective action.

Distribution

Predominantly intraluminal gastrointestinal activity; reported plasma protein binding approximately 67.5% in healthy subjects when measurable.

Excretion

Almost exclusively eliminated through faeces (mostly unchanged); only a very small proportion recovered in urine.

Adverse Effects Toxicity

Nausea, peripheral oedema and gastrointestinal symptoms; Clostridioides difficile-associated diarrhoea, serious hypersensitivity or cutaneous reactions can occur.

Special Points

Prevents recurrent hepatic encephalopathy but is not a substitute for correcting precipitants or providing appropriate acute encephalopathy care. Monitor for interactions and higher exposure in advanced cirrhosis; avoid unsupported claims that systemic exposure is literally zero.

Source references

These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.